Chennai based Bafna Pharmaceuticals Limited posted a topline of Rs. 2,142.87 lakhs, a growth of over 26% in the first quarter of FY 2021-22 against Rs. 1,687.80 lakhs in the corresponding period last year.

The profits for the period surged to Rs. 208.70 lakh as against Rs. 181.16 lakh last year, registering a robust growth of 15%. This robust growth has come despite the raging pandemic for most part of the quarter.

Navin Bafna, Head - Business Development, Bafna Pharma said, "This growth in numbers has been due to the collective efforts of the team who worked incredibly hard to achieve it in spite of the uncertainty and personal losses. Our business model and the government's vision of giving priority to Pharma products' exports and our consistent and unmatched service are the other major factors for this result.

"Going forward, we are also looking for organic growth by getting market authorizations in regulated markets of EU, UK, and Australia," added Navin Bafna.